UAS
BBH icon

United Asset Strategies’s VanEck Biotech ETF BBH Stock Holding History

United Asset Strategies’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-4,860
Closed -$333K – 88
2013
Q2 		$333K Buy
+4,860
New +$338K 0.22% 80

Other funds holding BBH

NCM
Niemann Capital Management Stateline, Nevada $788K AUM 23.27% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FMI
Factory Mutual Insurance Waltham, Massachusetts $8.89B AUM 25.87% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AHS
Aspiriant Holdings S3 Los Angeles, California $233M AUM 3.13% 1-Year Est. Return

United Asset Strategies's BBH Position: Q3 2013 in Review

United Asset Strategies sold out of VanEck Biotech ETF (BBH) in Q3 2013, closing a stake of 4,860 shares — an estimated $333K sold.

United Asset Strategies first reported a position in BBH in Q2 2013 and held it in 1 quarter. The position peaked at $333K in Q2 2013. 39 funds tracked by Wall St. Rank hold BBH as of Q3 2013.

  • United Asset Strategies reported no remaining VanEck Biotech ETF position as of Q3 2013 after selling out during the quarter.
  • United Asset Strategies sold 4,860 VanEck Biotech ETF shares in Q3 2013, an estimated $333K.
  • United Asset Strategies first reported a position in VanEck Biotech ETF in Q2 2013 and held it in 1 quarter.
  • United Asset Strategies's VanEck Biotech ETF position peaked at $333K in Q2 2013.
  • 39 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2013.

Based on United Asset Strategies's 13F filing for Q3 2013, filed 8 Nov 2013.